A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer
The reduced-dose FRα vaccine is as effective as the original dose and does not require CP to generate maximal immunity. These findings may inform the design of trials testing efficacy in triple-negative breast cancer or other cancers.
Authors
- Matthew Stephen Block (ORCID: https://orcid.org/0000-0001-5692-4219)
- Erika Hamilton (ORCID: https://orcid.org/0000-0002-1911-0336)
- Hadeel Assad (ORCID: https://orcid.org/0000-0002-1869-0199)
- Nadine Norton (ORCID: https://orcid.org/0000-0002-3848-4288)
- Keith L. Knutson (ORCID: https://orcid.org/0000-0001-9932-4467)
- Davitte Cogen (ORCID: https://orcid.org/0000-0001-5846-7066)
- Kristi McIntyre (ORCID: https://orcid.org/0009-0007-2120-8950)
- Priyanka Sharma (ORCID: https://orcid.org/0000-0001-8592-2239)
- Gerald Garrett (ORCID: https://orcid.org/0009-0003-1339-5654)
- Hala Abu‐Fares (ORCID: https://orcid.org/0000-0001-6585-9279)
- Hyo S. Han (ORCID: https://orcid.org/0000-0002-0072-0257)
- Stephanie L. Graff (ORCID: https://orcid.org/0000-0003-1928-1722)
- Patrick J. Ward (ORCID: https://orcid.org/0000-0002-7800-4840)
- Courtney L. Erskine (ORCID: https://orcid.org/0000-0001-8873-1542)
- G. Haswell Wilson (ORCID: https://orcid.org/0009-0008-9635-9769)
- Amy Tiersten (ORCID: https://orcid.org/0000-0002-4054-9140)
- Katherine Tkaczuk (ORCID: https://orcid.org/0000-0002-5978-5215)
- Aziza Nassar (ORCID: https://orcid.org/0000-0002-6678-9329)
- Richard T. Kenney (ORCID: https://orcid.org/0009-0008-6720-3298)
- Joseph A. Sparano (ORCID: https://orcid.org/0000-0002-9031-2010)
- Peter Keating (ORCID: https://orcid.org/0009-0000-2635-8703)
Institutions
- University of Maryland, Baltimore (US)
- Mayo Clinic (US)
- Montefiore Medical Center (US)
- Sarah Cannon Research Institute (GB)
- Brown University (US)
- Texas Oncology (US)
- Jacksonville College (US)
- WinnMed (US)
- Research Medical Center (US)
- Moffitt Cancer Center (US)
- Jacksonville University (US)
- The Barbara Ann Karmanos Cancer Institute (US)
- The University of Kansas Cancer Center (US)
- Sarah Cannon (US)
- Mount Sinai Hospital (US)
- Mayo Clinic in Arizona (US)
- University of Kansas Medical Center (US)
- Infinity Vision Dallas (US)
- Tennessee Oncology (US)
- Mayo Clinic in Florida (US)
- Universitas Muhammadiyah Tapanuli Selatan (ID)
- The US Oncology Network (US)
- Io Therapeutics (United States) (US)
- Oncology Hematology Care (US)
- US Biologic (United States) (US)
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
- Florida Atlantic University (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2763
- Citations
- 1
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- U.S. Department of Defense
- Breast Cancer Research Foundation
- Eli Lilly and Company
- AstraZeneca
- Genentech
- National Cancer Institute
- Daiichi Sankyo Europe
- Congressionally Directed Medical Research Programs